➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,018,992

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,018,992 protect, and when does it expire?

Patent 7,018,992 protects VAGIFEM and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 7,018,992
Title:Hormone composition
Abstract:Twice weekly administration of an analog to a Vagifem tablet which only contains 10 .mu.g of active material has a sufficient effect.
Inventor(s): Koch; Karen (Charlottenlund, DK), Kvorning; Ingelise (Bronshoj, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/016,858
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,018,992
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,018,992

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,018,992

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2000 01891Dec 15, 2000
Denmark2000 01892Dec 15, 2000
Denmark2000 01890Dec 15, 2000

International Family Members for US Patent 7,018,992

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 532521   Start Trial
Australia 2156702   Start Trial
Cyprus 1112542   Start Trial
Germany 10179223   Start Trial
Germany 20120246   Start Trial
Denmark 1343508   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.